BioNTech shares soar 8% in premarket as COVID-19 vaccines help revenues smash estimates

Shares in BioNTech surged 8% in U.S. premarket trading on Monday, after the German biotech’s first-quarter earnings revealed a windfall of revenue and profit amid the global push to vaccinate against COVID-19.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.